The muscle loss concern, while often overstated, remains clinically relevant for older or frail patientsresearch shows GLP-1-induced weight loss does not cause disproportionate muscle loss in middle-aged adults, but resistance training and adequate protein intake remain essential recommendations
Translation dysregulation in neurodegenerative diseases: a focus on ALS
In 2014, Novos Saxenda (liraglutide) became the first GLP-1 agonist approved for obesity
According to PubMed, recent comprehensive reviews document effects on cardiovascular protection (reduced major adverse cardiovascular events), neuroprotection (reduced neuroinflammation, potential effects on Alzheimer's pathology), renal protection (reduced albuminuria and renal decline), hepatic improvement (reduced steatosis and fibrosis markers), adipose tissue remodeling (enhanced mitochondrial biogenesis, beige adipocyte programming, reduced visceral fat inflammation), modulation of gut microbiota composition, and even preliminary signals in obstructive sleep apnoea, substance use disorders, and tumour biology (Lu et al., 2024, DOI
Further randomized controlled trials are needed to confirm these results